indazoles has been researched along with Obesity in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, Q; Li, W; Lou, J; Peng, C; Teng, Z; Xu, C; Yin, L; Zhang, C; Zhou, X | 1 |
| Antunes, E; Mónica, FZ | 1 |
| Guzzo, PR; Moore, NA; Sargent, BJ; Surman, MD | 1 |
| Aida, J; Hotta, N; Igawa, H; Ikoma, M; Kakegawa, K; Kaku, H; Kasai, S; Kawata, Y; Kina, A; Maekawa, T; Nagisa, Y; Nakayama, M; Noguchi, T; Okuda, S; Takahashi, M; Yamamoto, S | 1 |
| Cheruvallath, Z; Dougan, DR; Erikson, P; Farrell, P; Feng, J; Holub, C; Komandla, M; Larson, C; Lawson, JD; McBride, C; Miura, J; Plonowski, A; Tang, M; Ton-Nu, T; Vanderpool, D; Wu, Y | 1 |
| Cheetham, S; Freeman, EE; Grabowski, JF; Guzzo, PR; Hadden, M; Henderson, AJ; Jiang, G; Jiang, XM; Khmelnitsky, Y; Luche, M; Surman, MD; Vickers, S; Viggers, J | 1 |
| Lazzari, P; Mastinu, A; Pani, L; Pinna, GA; Pira, M | 1 |
| Choi, SE; Han, SJ; Hwang, YC; Jeoung, K; Jung, IR; Jung, JG; Kang, Y; Kim, DJ; Kim, HJ; Ku, JM; Lee, KW; Lee, SJ; Yi, SA | 1 |
| Hayashi, A; Kimura, Y; Miyata, K; Sasamata, M; Sonoda, R; Suzuki, M; Takasu, T | 1 |
| Brodjian, S; Brune, M; Bush, E; Collins, CA; Dayton, B; Gao, J; Hernandez, LE; Judd, AS; Kym, PR; Marsh, KC; Mulhern, M; Sham, HL; Shapiro, R; Souers, AJ; Vasudevan, A; Wodka, D | 1 |
| Brodjian, SJ; Brune, ME; Bush, EN; Collins, CA; Dayton, BD; Gao, J; Hernandez, LE; Judd, AS; Kym, PR; Marsh, KC; Mulhern, MM; Napier, JJ; Sham, HL; Shapiro, R; Souers, AJ; Wodka, D | 1 |
| Johns, EJ; Wongmekiat, O | 1 |
2 review(s) available for indazoles and Obesity
| Article | Year |
|---|---|
Stimulators and activators of soluble guanylate cyclase for urogenital disorders.
Topics: Aging; Animals; Benzoates; Diabetes Complications; Enzyme Activators; Humans; Hypertension; Indazoles; Lower Urinary Tract Symptoms; Nitric Oxide; Obesity; Phosphodiesterase 5 Inhibitors; Pyrazoles; Pyridines; Reactive Oxygen Species; Risk Factors; Soluble Guanylyl Cyclase; Urinary Tract | 2018 |
From preclinical to clinical development: the example of a novel treatment for obesity.
Topics: Animals; Anti-Obesity Agents; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Humans; Indazoles; Male; Obesity; Pyridones; Rats; Receptors, Pituitary Hormone | 2014 |
10 other study(ies) available for indazoles and Obesity
| Article | Year |
|---|---|
Prevention of Obesity Related Diseases through Laminarin-induced targeted delivery of Bindarit.
Topics: Adipose Tissue; Animals; Atherosclerosis; Computer Simulation; Diet, High-Fat; Fatty Liver; Glucans; Humans; Indazoles; Inflammation; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Monocytes; Nanoparticles; Obesity; Plaque, Atherosclerotic; Propionates | 2020 |
Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel non-basic 1-(2H-indazole-5-yl)pyridin-2(1H)-one derivatives and mitigation of mutagenicity in Ames test.
Topics: Animals; Anti-Obesity Agents; Dose-Response Relationship, Drug; Humans; Indazoles; Male; Molecular Structure; Obesity; Pyridones; Rats; Rats, Inbred F344; Receptors, Somatostatin; Structure-Activity Relationship | 2016 |
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1.
Topics: Administration, Oral; Aminopeptidases; Animals; Body Weight; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Glycoproteins; Humans; Indazoles; Methionyl Aminopeptidases; Mice; Mice, Obese; Models, Molecular; Molecular Structure; Obesity; Structure-Activity Relationship | 2016 |
5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.
Topics: Animals; Anti-Obesity Agents; Cardiovascular Diseases; Ether-A-Go-Go Potassium Channels; Humans; Indazoles; Mice; Obesity; Receptors, Pituitary Hormone; Structure-Activity Relationship | 2010 |
NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
Topics: Analysis of Variance; Animals; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Body Weight; Brain-Derived Neurotrophic Factor; Cannabinoid Receptor Antagonists; Cholesterol; Dietary Fats; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypothalamus; Indazoles; Intra-Abdominal Fat; Liver; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factor; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Serotonin Plasma Membrane Transport Proteins; Thiophenes; Transaminases; Triglycerides | 2012 |
A compound (DW1182v) protecting high glucose/palmitate-induced glucolipotoxicity to INS-1 beta cells preserves islet integrity and improves hyperglycemia in obese db/db mouse.
Topics: Animals; Blood Glucose; Cell Line; Cell Survival; Endoplasmic Reticulum Stress; Glucose; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Indazoles; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Obese; Obesity; Palmitates; Pyrimidines | 2012 |
Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats.
Topics: Aminopyridines; Animals; Anti-Obesity Agents; Blood Glucose; Body Temperature; Body Weight; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Eating; Energy Intake; Indazoles; Indoles; Insulin; Lipids; Male; Obesity; Rats; Rats, Zucker; Serotonin 5-HT2 Receptor Agonists; Serotonin Antagonists; Time Factors; Weight Gain | 2004 |
Identification of 2-(4-benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity.
Topics: Acetamides; Administration, Oral; Animals; Anti-Obesity Agents; Binding, Competitive; Brain; Calcium; Chronic Disease; Indazoles; Mice; Obesity; Pyrrolidines; Radioligand Assay; Receptors, Somatostatin; Structure-Activity Relationship; Tissue Distribution | 2005 |
Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.
Topics: Animals; Indazoles; Mice; Obesity; Receptors, Somatostatin; Structure-Activity Relationship; Urea | 2005 |
Interactions between nitric oxide and renal nerves in the excretion of a saline load in obese Zucker rats.
Topics: Animals; Blood Glucose; Diuresis; Enzyme Inhibitors; Guanidines; Hemodynamics; Indazoles; Kidney; Male; Natriuresis; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Obesity; Rats; Rats, Zucker | 2001 |